论文部分内容阅读
目的探讨Ki-67和乙醛脱氢酶1(ALDH1)联合检测对判断三阴性乳腺癌(TNBC)新辅助化疗(NACT)效果的价值。方法回顾性分析完成NACT的52例TNBC患者资料,分析化疗前Ki-67和ALDH1的不同表达情况与NACT后病理完全缓解(pCR)之间的相关性。结果 52例中,20例(38.5%)NACT后获得pCR。Ki-67阳性表达组pCR率65.2%(15/23),高于Ki-67阴性表达组的17.2%(5/29)(P<0.05)。ALDH1阳性表达组pCR率15.6%(5/32),低于ALDH1阴性表达组的75.0%(15/20)(P<0.01)。Ki-67阳性且ALDH1阴性表达组pCR率为93.8%(15/16),高于Ki-67阳性且ALDH1阳性表达组或Ki-67阴性且ALDH1阳性表达组(P<0.05)。结论 TNBC组织中Ki-67阳性且ALDH1阴性表达患者对NACT效果好,Ki-67阳性且ALDH1阴性可作为预测TNBC的NACT疗效的分子标记物。
Objective To investigate the value of combined detection of Ki-67 and aldehyde dehydrogenase 1 (ALDH1) in judging the effect of neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC). Methods The data of 52 TNBC patients who completed NACT were retrospectively analyzed. The correlation between the different expressions of Ki-67 and ALDH1 and the post-NACT complete remission (pCR) before chemotherapy was analyzed. Results In 52 cases, 20 cases (38.5%) obtained pCR after NACT. The pCR rate of Ki-67 positive group was 65.2% (15/23), which was higher than that of Ki-67 negative group (17.2%, 5/29) (P <0.05). The pCR rate in ALDH1 positive group was 15.6% (5/32), which was lower than that in ALDH1 negative group (75.0%, 15/20) (P <0.01). The pCR rate was 93.8% (15/16) in Ki-67-positive and ALDH1-negative groups, which was higher than that in Ki-67-positive and ALDH1-positive or Ki-67-negative and ALDH1-positive groups (P <0.05). Conclusion The patients with Ki-67 positive and ALDH1 negative expression in TNBC tissues have good effect on NACT, Ki-67 positive and ALDH1 negative can be used as molecular markers to predict the NACT efficacy of TNBC.